- Home
- MYNZ vs BDRX Comparison
MYNZ vs BDRX Comparison
Compare MYNZ & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- BDRX
- Stock Information
- Founded
- MYNZ 2021
- BDRX 2000
- Country
- MYNZ Germany
- BDRX United Kingdom
- Employees
- MYNZ N/A
- BDRX N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- BDRX Health Care
- Exchange
- MYNZ Nasdaq
- BDRX Nasdaq
- Market Cap
- MYNZ 7.9M
- BDRX 3.9M
- IPO Year
- MYNZ 2021
- BDRX N/A
- Fundamental
- Price
- MYNZ $1.50
- BDRX $6.75
- Analyst Decision
- MYNZ Buy
- BDRX
- Analyst Count
- MYNZ 2
- BDRX 0
- Target Price
- MYNZ $14.00
- BDRX N/A
- AVG Volume (30 Days)
- MYNZ 515.8K
- BDRX 350.4K
- Earning Date
- MYNZ 09-26-2025
- BDRX 09-12-2025
- Dividend Yield
- MYNZ N/A
- BDRX N/A
- EPS Growth
- MYNZ N/A
- BDRX N/A
- EPS
- MYNZ N/A
- BDRX N/A
- Revenue
- MYNZ $659,935.00
- BDRX N/A
- Revenue This Year
- MYNZ $26.06
- BDRX N/A
- Revenue Next Year
- MYNZ $4.97
- BDRX N/A
- P/E Ratio
- MYNZ N/A
- BDRX N/A
- Revenue Growth
- MYNZ N/A
- BDRX N/A
- 52 Week Low
- MYNZ $1.28
- BDRX $5.00
- 52 Week High
- MYNZ $14.39
- BDRX $92.00
- Technical
- Relative Strength Index (RSI)
- MYNZ 46.56
- BDRX 45.80
- Support Level
- MYNZ $1.37
- BDRX $7.21
- Resistance Level
- MYNZ $1.73
- BDRX $7.71
- Average True Range (ATR)
- MYNZ 0.15
- BDRX 1.00
- MACD
- MYNZ -0.00
- BDRX -0.17
- Stochastic Oscillator
- MYNZ 53.18
- BDRX 7.57
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.